Author

Gil Y. Melmed

UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY

Gil Y. Melmed  et al.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Gil Y. Melmed  et al.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Gil Y. Melmed  et al.

RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY
RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Gil Y. Melmed  et al.

Item 1 - 4 / 4
1